NasdaqCM - Nasdaq Real Time Price USD

Daré Bioscience, Inc. (DARE)

0.2892

+0.0032

(+1.12%)

At close: April 25 at 4:00 PM EDT

0.2998

+0.01

(+3.67%)

After hours: April 25 at 7:01 PM EDT

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged Treatment SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will

GlobeNewswire 2 days ago

DARE
+1.12%
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has the potential to be the first FDA-approved hormone-free monthly intravaginal contraceptive for women SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of data from the postcoital test clinical study

GlobeNewswire 14 days ago

DARE
+1.12%
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript

Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript March 28, 2024 Daré Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.12. DARE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the conference call hosted […]

Insider Monkey 24 days ago

DARE
+1.12%
Q4 2023 Dare Bioscience Inc Earnings Call

Q4 2023 Dare Bioscience Inc Earnings Call

Thomson Reuters StreetEvents 27 days ago

DARE
+1.12%
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ET2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license agreement with commercial collaborator OrganonOvaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United StatesSildenafil Cream, 3.6% topical formulation of sildenafil being devel

GlobeNewswire 28 days ago

DARE
+1.12%
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year ended December 31, 2023 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (international). The conference ID number for the call is 7156675

GlobeNewswire last month

DARE
+1.12%
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND clinical study, as well as improvement in multiple aspects of the sexual experience Continuing to work toward Phase 3 pivotal study There are no FDA-approved treatments for female sexual arousal disorder SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that additional data from the e

GlobeNewswire 2 months ago

DARE
+1.12%
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

There are no FDA-approved treatments for female sexual arousal disorderSAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the successful completion of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting advancement of Sildenafil Cream, 3.6% (Sil

GlobeNewswire 2 months ago

DARE
+1.12%
Daré Bioscience Announces Executive Team and Board of Directors Changes

SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors t

GlobeNewswire 2 months ago

DARE
+1.12%
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newbornsSAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $750,000 to fund activities related to bacteria-based live biotherapeutic product development. Daré previously received a grant

GlobeNewswire 3 months ago

DARE
+1.12%
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and Other Conditions Requiring Precise, Prolonged TreatmentSAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has achieved technological proof of concept for DARE-LARC1 and the underlying innovative drug delivery platform designed to store and precisely deli

GlobeNewswire 3 months ago

DARE
+1.12%
When Will Daré Bioscience, Inc. (NASDAQ:DARE) Become Profitable?

Daré Bioscience, Inc. ( NASDAQ:DARE ) is possibly approaching a major achievement in its business, so we would like to...

Simply Wall St. 3 months ago

DARE
+1.12%
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

$5 million at closing and up to $7 million of additional committed fundingSAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at closing and up to an additional $7 million through three tranches over time at Daré’s option. The financing structure entitles the investor to a percentage of the royalties and milestones to be

GlobeNewswire 3 months ago

DARE
+1.12%
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary DysmenorrheaSAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1. DARE-PDM1 is an investigational product designed to deliver diclofenac, a nonsteroidal anti-infl

GlobeNewswire 4 months ago

DARE
+1.12%
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

DARE-PTB1 is being developed as a treatment to reduce the risk of preterm birth, for which there are no FDA-approved treatment options Up to approximately $2 million in grant funding to support DARE-PTB1 Phase 1 human clinical study SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Develo

GlobeNewswire 4 months ago

DARE
+1.12%
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause

DARE-VVA1 has the potential to be the first therapeutic non-hormonal vaginal option for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) in women who cannot or should not take supplemental estrogenSAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for DARE-VVA

GlobeNewswire 4 months ago

DARE
+1.12%
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced commencement of the Company’s pivotal Phase 3 clinical study of Ovaprene, an investigational hormone-free monthly intravaginal contraceptive. The multi-center, single arm, non-comparative, pivotal Phase 3 clinical study of Ovaprene will evaluat

GlobeNewswire 4 months ago

DARE
+1.12%
20 Countries with the Highest Teenage Pregnancy Rates

In this article, we will be navigating through adolescent fertility across the world while covering the 20 countries with the highest teenage pregnancy rates. If you wish to skip our detailed analysis, you can move directly to the 5 Countries with the Highest Teenage Pregnancy Rates. Adolescent Pregnancy Across the Globe Early pregnancy and motherhood […]

Insider Monkey 4 months ago

FEMY

DARE
+1.12%
Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

Partnership Aims to Advance Daré’s Reproductive Health Portfolio in a Timely and Capital Efficient MannerSAN DIEGO and MORRISVILLE, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Premier Research International, LLC, a global clinical research, product development, and consulting company, today announced that the companies extended their partnership agreement under which Premier Research will continue to provide on an exclu

GlobeNewswire 5 months ago

DARE
+1.12%
Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that an overview of the preliminary efficacy findings from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% (Sildenafil Cream) in women with female sexual arousal disorder (FSAD) will be presented at the upcoming

GlobeNewswire 5 months ago

DARE
+1.12%

Performance Overview

Return	DARE	S&P 500
YTD	-6.41%	+5.84%
1-Year	-71.65%	+22.03%
3-Year	-80.46%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Daré Bioscience, Inc. (DARE)

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript

Q4 2023 Dare Bioscience Inc Earnings Call

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

When Will Daré Bioscience, Inc. (NASDAQ:DARE) Become Profitable?

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

20 Countries with the Highest Teenage Pregnancy Rates

Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

Performance Overview